Novartis has the most new approvals, but Lilly’s are worth more
When it comes to big pharma’s novel therapies, it is a case of quantity versus quality.
Esmo 2022 – Regeneron stakes its Lag3 claim
Fianlimab maintains its leading activity, but more Opdualag competition is not far behind.
Horizon still has a mountain to climb
But positive mid-stage Sjögren’s data raise hopes for others still plugging away at anti-CD40 assets.
Esmo 2022 – Springworks aims to Defi expectations
Data in the desmoid tumour niche look strong, but Ayala might provide a cheaper way for investors to play in gamma secretase inhibition.
Esmo 2022 – the new liver cancer entrants line up
Late-breakers give tislelizumab, camrelizumab and Keytruda outside chances to add to the first-line armamentarium.
